Dopamine D2 receptor antagonism of antipsychotics and the risk of death due to choking

Psychiatry Res. 2024 Sep:339:116012. doi: 10.1016/j.psychres.2024.116012. Epub 2024 Jun 3.

Abstract

The risk of fatal choking for people with schizophrenia and associations with antipsychotic medication are largely unknown. Therefore, we calculated the choking-related standardized mortality ratio for schizophrenia relative to the general population (SMRchoking). We also computed adjusted hazard ratios (aHR) of choking-related mortality for antipsychotics in a nationwide cohort of patients with schizophrenia (N = 59,916). SMRchoking was 20.5 (95 % confidence interval (CI)=17.1-23.9). The aHR was 1.74 (95 %CI=1.19-2.55) for strong dopamine 2-antagonists. For other antipsychotics, CIs included 1. Importantly, aHRs were particularly high for high dose categories of strong dopamine D2 receptor (D2R) antagonists. In conclusion, a schizophrenia diagnosis is associated with a 20-fold risk of death due to choking. This risk is elevated during use of strong D2R antagonist antipsychotics, particularly when prescribed in high dosages.

Keywords: Antipsychotic; Choking; Clozapine; Olanzapine; Pneumonia; Quetiapine; Schizophrenia.

MeSH terms

  • Adult
  • Aged
  • Antipsychotic Agents* / adverse effects
  • Cohort Studies
  • Dopamine D2 Receptor Antagonists* / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Receptors, Dopamine D2 / metabolism
  • Schizophrenia* / drug therapy
  • Schizophrenia* / mortality
  • Young Adult

Substances

  • Antipsychotic Agents
  • Dopamine D2 Receptor Antagonists
  • Receptors, Dopamine D2